


- AZA has also been evaluated for remission maintenance
- Initial reports from open-label series suggested that AZA may be able to maintain remission following induction with daily CYC

Fauci A, Haynes. *Ann Intern Med* 83, 98:76-85

Conclusions







In patients with generalized vasculitis, the withdrawal of cyclophosphamide and the substitution of azathioprine after remission did not increase the rate of relapse. Thus, the duration of exposure to cyclophosphamide may be safely reduced.

N Engl J Med 2003; 349: 36-44



Rituximab for Refractory Wegener's Granulomatosis

Report of a Prospective, Open-Label Pilot Trial




Rituximab was a well-tolerated and effective remission induction agent for severe refractory Wegener's granulomatosis

Etanercept plus Standard Therapy for Wegener's Granulomatosis

Conclusions

Etanercept is not effective for the maintenance of remission in patients with Wegener's granulomatosis. Durable remissions were achieved in only a minority of the patients, and there was a high rate of treatment-related complications



Complications

In ANCA-associated systemic vasculitides after patients have begun treatment with corticosteroids and cytotoxic drugs, the recurrence of pulmonary symptoms suggesting a flare indicates a careful search for an opportunistic lung infection or iatrogenic pulmonary complication

Iatrogenic Pulmonary Complications

Chronic Interstitial Pneumonitis (NSIP)

cyclophosphamide, methotrexate

Diffuse Alveolar Damage

azathioprine, cyclophosphamide, methotrexate

Bronchiolitis Obliterans – Organizing Pneumonia

cyclophosphamide, methotrexate

Haemorrhagic Alveolitis

cyclophosphamide

Pulmonary Oedema

methotrexate

Granulomatous reaction

methotrexate

